加载中
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
常规交易时段
US$3.62
−US$0.01 · -0.28%
盘中时间采用ET。市场数据可能有所延迟。
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
日内区间
当前US$3.62
52周区间
当前US$3.62
盘中时间采用ET。市场数据可能有所延迟。
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
日内区间
当前US$3.62
52周区间
当前US$3.62
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（AUD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 1423.88万 AUD | 504.38万 AUD | 384.19万 AUD | 350.57万 AUD | 17.04万 AUD |
| 销货成本 | 241.91万 AUD | 6141.05万 AUD | 4154.67万 AUD | 206.18万 AUD | 206.35万 AUD |
| 毛利 | 1181.97万 AUD | −5636.68万 AUD | −3770.48万 AUD | 144.39万 AUD | −189.31万 AUD |
| 研究与开发 | 7498.17万 AUD | 6141.05万 AUD | 4154.67万 AUD | 2879.34万 AUD | 3134.16万 AUD |
| 销售、一般及管理费用 | 1888.38万 AUD | 864.45万 AUD | 885.26万 AUD | 1408.18万 AUD | 721.01万 AUD |
| 营业费用 | 9386.56万 AUD | 7005.5万 AUD | 5039.93万 AUD | 4493.7万 AUD | 3254.77万 AUD |
| 利息收入 | 293.94万 AUD | 525.01万 AUD | 388.28万 AUD | 93.9万 AUD | 22.45万 AUD |
| 利息支出 | 6.64万 AUD | — | 3.06万 AUD | 2.04万 AUD | 9.24万 AUD |
| 折旧和摊销 | 241.91万 AUD | 248.7万 AUD | 217.24万 AUD | 203.01万 AUD | 206.45万 AUD |
| 营业利润 | −8204.58万 AUD | −1.26亿 AUD | −8810.42万 AUD | −7768.85万 AUD | −3393.76万 AUD |
| 净利润 | −7757.17万 AUD | −6143.42万 AUD | −4271.66万 AUD | −3989.63万 AUD | −3221.08万 AUD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
